Skip to main content

Main menu

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Subscriptions
  • Alerts
  • Log in

Search

  • Advanced search
British Journal of General Practice
Intended for Healthcare Professionals
  • RCGP
    • BJGP for RCGP members
    • BJGP Open
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
  • Listen to BJGP podcast
  • Subscribe BJGP on YouTube
British Journal of General Practice
Intended for Healthcare Professionals

Advanced Search

  • HOME
  • ONLINE FIRST
  • CURRENT ISSUE
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • SUBSCRIBE
  • BJGP LIFE
  • MORE
    • About BJGP
    • Conference
    • Advertising
    • eLetters
    • Alerts
    • Video
    • Audio
    • Librarian information
    • Resilience
    • COVID-19 Clinical Solutions
Out of Hours

Keep an eye on the SSRI: help avoid possible sight-threatening adverse events

Jonathan Lochhead
British Journal of General Practice 2016; 66 (643): 91. DOI: https://doi.org/10.3399/bjgp16X683641
Jonathan Lochhead
St Mary’s Hospital, Newport, Isle of Wight.
Roles: Consultant Ophthalmologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info
  • eLetters
  • PDF
Loading

A recent report in a peer-reviewed UK journal outlines five cases of optic neuropathy thought to be related to long-term treatment with selective serotonin reuptake inhibitors (SSRIs).1 These five were identified over a 2-year period within an island population of 140 000. Each case was assessed using the Naranjo algorithm to indicate likelihood of adverse drug reaction (ADR).2 The Naranjo scores indicated possible ADR in four cases and probable ADR in one case.

All five cases presented with visual loss from suspected ischaemic optic neuropathy (ION) and were all extensively investigated for any other possible underlying cause. A ‘non-arteritic’ ischaemic origin was suspected in all cases. Toxicity was felt to be unlikely since three cases were of sudden onset and two cases were unilateral.

Two cases experienced progressive bilateral visual field (VF) loss. Two cases presented with severe unilateral sudden loss of vision (SLOV), and one patient had bilateral SLOV. All patients were relatively young (mean 49 years, range 40–54 years) with a long history of SSRI treatment with a mean of 7 years (range 1–14 years).

All cases were able to discontinue SSRIs without any further deterioration. One patient with bilateral progressive LOV recovered completely over 18 months. Two patients with unilateral SLOV did not recover function in the affected eye but retained normal vision in the second eye.

One case was diagnosed with anterior ION (involving short posterior ciliary arteries) which presents with sudden optic disc swelling associated with altitudinal visual field loss. Four cases had clinical features of posterior ION (involving pial branches of central retinal artery) which are typically normal disc appearance at the outset with acute or progressive, painless LOV in one or both eyes.

Posterior ION in relatively young healthy patients is rare. Systemic risk factors for ION include cardiovascular disease, diabetes, and hypertension. Two of the patients reported suffered with non-insulin-dependent diabetes mellitus and three were smokers.

All patients were able to stop taking SSRIs without any further deterioration. One patient with bilateral involvement recovered completely after 18 months, and one patient remained stable for 6 months until restarting an SSRI, after which she declined rapidly to count fingers vision in both eyes.

POSSIBLE SSRI SIDE EFFECTS

With long-term SSRI treatment it has been suggested that multiple transient vasospasms in the optic nerve could progressively induce a manifest ischaemic optic neuropathy. This has already been predicted pharmacologically. Costagliola et al described a mechanism for vasospasm in the optic nerve, postulating that increased plasma serotonin levels may be a factor, or a cofactor, in the development of optic nerve perfusion disorders.3 In individuals with atherosclerotica the susceptibility becomes higher due to serotonin-enhancing platelet aggregation on atheromata of ocular arteries.3,4

The most commonly-reported ophthalmic side effect of SSRIs is acute glaucoma. There is a single report of central retinal vein thrombosis in association with citalopram. The literature now contains reports of suspected associations with other thromboembolic events such as deep vein thrombosis and ischaemic stroke.1

The ION described before may be related to prolonged treatment and possibly also interacts with other risk factors such as smoking and diabetes. I recommend a review of SSRI treatment in cases of acute optic neuropathy, and advise caution when prescribing SSRIs.

In conjunction with known systemic vascular risk factors or pre-existing vascular eye disease. In 2004, approximately 7% of the UK adult population were receiving SSRI treatment for a range of 4.8–7.7 years.5

DON’T LOSE SIGHT OF THE DANGERS!

I believe we are indeed beginning to see evidence of ocular ischaemic events in otherwise reasonably healthy young adults, seemingly associated with long duration of SSRI treatment. This is perhaps a timely reminder that these drugs should not be prescribed with impunity and the need for ongoing, regular re-evaluation of patients taking SSRIs.

The number of potential puns seems endless, but I’ll settle for … Keep an eye on the SSRI !

  • © British Journal of General Practice 2016

REFERENCES

  1. 1.↵
    1. Lochhead J
    (2015) SSRI-associated optic neuropathy. Eye (Lond) 29(9):1233–1235.
    OpenUrlPubMed
  2. 2.↵
    1. Naranjo CA,
    2. Busto U,
    3. Sellers EM,
    4. et al.
    (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Costagliola C,
    2. Parmeggiani F,
    3. Semeraro F,
    4. Sebastiani A
    (2008) Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol 6(4):293–310.
    OpenUrlPubMed
  4. 4.↵
    1. Hayreh SS
    (1999) Retinal and optic nerve head ischemic disorders and atherosclerosis: role of serotonin. Prog Retin Eye Res 18(2):191–221.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Petty R,
    2. House A,
    3. Knapp P,
    4. et al.
    (2006) Prevalence, duration and indications for prescribing of antidepressants in primary care. Age Ageing 35(5):523–526.
    OpenUrlCrossRefPubMed
Back to top
Previous ArticleNext Article

In this issue

British Journal of General Practice: 66 (643)
British Journal of General Practice
Vol. 66, Issue 643
February 2016
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Or,
sign in or create an account with your email address
Email Article

Thank you for recommending British Journal of General Practice.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Keep an eye on the SSRI: help avoid possible sight-threatening adverse events
(Your Name) has forwarded a page to you from British Journal of General Practice
(Your Name) thought you would like to see this page from British Journal of General Practice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Keep an eye on the SSRI: help avoid possible sight-threatening adverse events
Jonathan Lochhead
British Journal of General Practice 2016; 66 (643): 91. DOI: 10.3399/bjgp16X683641

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Keep an eye on the SSRI: help avoid possible sight-threatening adverse events
Jonathan Lochhead
British Journal of General Practice 2016; 66 (643): 91. DOI: 10.3399/bjgp16X683641
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • POSSIBLE SSRI SIDE EFFECTS
    • DON’T LOSE SIGHT OF THE DANGERS!
    • REFERENCES
  • Info
  • eLetters
  • PDF

More in this TOC Section

  • The chronotherapy of hypertension: or the benefit of taking blood pressure tablets at bedtime
  • Every home should have one: the critical role of the research librarian
  • Fakery and science
Show more Out of Hours

Related Articles

Cited By...

Intended for Healthcare Professionals

BJGP Life

BJGP Open

 

@BJGPjournal's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Current Issue
  • All Issues
  • Online First
  • Authors & reviewers

RCGP

  • BJGP for RCGP members
  • BJGP Open
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Subscriber login
  • Activate subscription
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP: research
  • Writing for BJGP: other sections
  • BJGP editorial process & policies
  • BJGP ethical guidelines
  • Peer review for BJGP

CUSTOMER SERVICES

  • Advertising
  • Contact subscription agent
  • Copyright
  • Librarian information

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: journal@rcgp.org.uk

British Journal of General Practice is an editorially-independent publication of the Royal College of General Practitioners
© 2023 British Journal of General Practice

Print ISSN: 0960-1643
Online ISSN: 1478-5242